Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Tools from the World of Artificial Intelligence in Interventional Oncology: Be Careful What You Wish For.

Geschwind JH, Hochster HS.

J Vasc Interv Radiol. 2019 Mar;30(3):339-341. doi: 10.1016/j.jvir.2019.01.013. No abstract available.

PMID:
30819474
2.

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.

Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar J, Chiorean EG, Shields AF, Behl D, Mehan PT, Gaur R, Seery T, Guthrie KA, Hochster HS.

J Clin Oncol. 2019 Feb 28:JCO1801295. doi: 10.1200/JCO.18.01295. [Epub ahead of print]

PMID:
30817250
3.

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).

Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz HJ, Hochster HS, Scappaticci F, Palma JF, Price R, Lee JJ, Nicholas A, Sommer N, Bendell J.

Oncologist. 2018 Dec 14. pii: theoncologist.2018-0344. doi: 10.1634/theoncologist.2018-0344. [Epub ahead of print]

PMID:
30552157
4.

Should next-generation sequencing testing be routinely used in metastatic colorectal cancer?

Dienstmann R, Ciner A, Hochster HS.

Lancet Oncol. 2018 Nov;19(11):1434-1435. doi: 10.1016/S1470-2045(18)30776-9. Epub 2018 Nov 1. No abstract available.

PMID:
30507475
5.

Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation.

Amodeo S, Masi A, Melis M, Ryan T, Hochster HS, Cohen DJ, Chandra A, Pachter HL, Newman E.

J Gastrointest Oncol. 2018 Oct;9(5):922-935. doi: 10.21037/jgo.2017.10.04.

6.

Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.

Mayer RJ, Hochster HS, Cohen SJ, Winkler R, Makris L, Grothey A.

Cancer Chemother Pharmacol. 2018 Dec;82(6):961-969. doi: 10.1007/s00280-018-3686-5. Epub 2018 Oct 22.

PMID:
30350179
7.

Genomic mutations and histopathologic biomarkers in Y90 radioembolization for chemorefractory colorectal liver metastases.

Dendy MS, Ludwig JM, Kokabi N, Stein SM, Lacy J, Hochster HS, Kim HS.

Oncotarget. 2018 Aug 21;9(65):32523-32533. doi: 10.18632/oncotarget.25992. eCollection 2018 Aug 21.

8.

Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Jul;16(7):874-901. doi: 10.6004/jnccn.2018.0061.

PMID:
30006429
9.

Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Jul;16(7):852-871. doi: 10.6004/jnccn.2018.0060.

PMID:
30006428
10.

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer.

Mehrvarz Sarshekeh A, Xiong HQ, Iizuka K, Hochster HS, Kopetz S.

Invest New Drugs. 2018 Oct;36(5):895-902. doi: 10.1007/s10637-018-0615-8. Epub 2018 Jun 13.

PMID:
29948357
11.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
12.

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL.

Clin Cancer Res. 2018 Oct 1;24(19):4734-4744. doi: 10.1158/1078-0432.CCR-17-1523. Epub 2018 Jun 5.

PMID:
29871907
13.

NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021.

PMID:
29632055
14.

Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713.

Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS.

Clin Colorectal Cancer. 2018 Mar;17(1):e121-e125. doi: 10.1016/j.clcc.2017.10.008. Epub 2017 Oct 24.

PMID:
29233486
15.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C.

JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105.

16.

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.

Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS.

J Clin Oncol. 2017 May 20;35(15):1695-1703. doi: 10.1200/JCO.2016.70.4072. Epub 2017 Apr 6.

17.

Metastatic Colorectal Cancer: Management With Trifluridine/Tipiracil
.

White T, Larson H, Minnella A, Hochster HS.

Clin J Oncol Nurs. 2017 Apr 1;21(2):E30-E37. doi: 10.1188/17.CJON.E30-E37. Review.

PMID:
28315543
18.

A Long-Term Survivor of Metastatic Pancreatic Adenocarcinoma: Free of Recurrence 12 Years After Treatment of Oligometastatic Disease.

Stahl JM, Walther Z, Chang BW, Hochster HS, Johung KL.

Cureus. 2017 Feb 2;9(2):e1007. doi: 10.7759/cureus.1007.

19.

Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.

Langdon CG, Platt JT, Means RE, Iyidogan P, Mamillapalli R, Klein M, Held MA, Lee JW, Koo JS, Hatzis C, Hochster HS, Stern DF.

Mol Cancer Ther. 2017 Jun;16(6):1041-1053. doi: 10.1158/1535-7163.MCT-16-0794. Epub 2017 Mar 14.

20.

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D.

J Natl Compr Canc Netw. 2017 Mar;15(3):370-398.

PMID:
28275037
21.

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.

Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS.

JAMA Oncol. 2017 Apr 1;3(4):516-522. doi: 10.1001/jamaoncol.2016.5383.

22.

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.

Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A, Yoshino T.

BMC Cancer. 2016 Jul 13;16:467. doi: 10.1186/s12885-016-2491-y.

23.

Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).

Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Colocci N, Bengtson EM, Horning SJ, Kahl BS.

Cancer. 2016 Oct;122(19):2996-3004. doi: 10.1002/cncr.30137. Epub 2016 Jun 28.

24.

Single-Agent Therapies After Standard Combination Regimens.

Chokshi S, Hochster HS.

Cancer J. 2016 May-Jun;22(3):205-10. doi: 10.1097/PPO.0000000000000198. Review.

PMID:
27341600
25.

From the Guest Editor: Updates in Colorectal Cancer.

Hochster HS.

Cancer J. 2016 May-Jun;22(3):147-8. doi: 10.1097/PPO.0000000000000207. No abstract available.

PMID:
27341590
26.

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.

Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J.

Br J Cancer. 2016 Mar 29;114(7):737-43. doi: 10.1038/bjc.2016.45.

27.

Big Data, Small Effects.

Hochster HS, Niedzwiecki D.

J Clin Oncol. 2016 Apr 10;34(11):1170-1. doi: 10.1200/JCO.2015.65.8161. Epub 2016 Feb 16. No abstract available.

PMID:
26884573
28.

One good DNA-damage deserves another: Oxaliplatin in MSI-high colon cancer.

Hochster HS, Sargent DJ.

J Natl Cancer Inst. 2016 Feb 5;108(7). pii: djw011. doi: 10.1093/jnci/djw011. Print 2016 Jul. No abstract available.

PMID:
26851803
29.

Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.

Leichman L, Groshen S, O'Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Cason RC, Hamilton SR, Hochster HS.

Oncologist. 2016 Feb;21(2):172-7. doi: 10.1634/theoncologist.2015-0319. Epub 2016 Jan 19.

30.

TAS-102: a novel antimetabolite for the 21st century.

Uboha N, Hochster HS.

Future Oncol. 2016 Jan;12(2):153-63. doi: 10.2217/fon.15.276. Epub 2015 Nov 30. Review.

31.

Rectal Cancer, Version 2.2015.

Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D.

J Natl Compr Canc Netw. 2015 Jun;13(6):719-28; quiz 728.

PMID:
26085388
32.

Cancer stem cells: the promise and the potential.

Ajani JA, Song S, Hochster HS, Steinberg IB.

Semin Oncol. 2015 Apr;42 Suppl 1:S3-17. doi: 10.1053/j.seminoncol.2015.01.001. Epub 2015 Jan 21. Review.

PMID:
25839664
33.

Introduction.

Ajani JA, Song S, Hochster HS, Steinberg IB.

Semin Oncol. 2015 Apr;42 Suppl 1:S1-2. doi: 10.1053/j.seminoncol.2015.02.020. Epub 2015 Feb 19. No abstract available.

PMID:
25839663
34.

The bipartisan colon.

Hochster HS.

J Natl Cancer Inst. 2015 Feb 24;107(3). pii: djv011. doi: 10.1093/jnci/djv011. Print 2015 Mar. No abstract available.

PMID:
25713149
35.

Chronic thalidomide and chemoembolization for hepatocellular carcinoma.

Wu J, Ng J, Christos PJ, Goldenberg AS, Sparano J, Sung MW, Hochster HS, Muggia FM.

Oncologist. 2014 Dec;19(12):1229-30. doi: 10.1634/theoncologist.2014-0283. Epub 2014 Oct 31.

36.

Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.

Li J, Yao X, Kortmansky JS, Fischbach NA, Stein S, Deng Y, Zhang Y, Doddamane I, Karimeddini D, Hochster HS, Lacy J.

Am J Clin Oncol. 2017 Apr;40(2):146-151. doi: 10.1097/COC.0000000000000114.

PMID:
25144267
37.

A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.

Stein SM, Tiersten A, Hochster HS, Blank SV, Pothuri B, Curtin J, Shapira I, Levinson B, Ivy P, Joseph B, Guddati AK, Muggia F.

Int J Gynecol Cancer. 2013 Nov;23(9):1577-82. doi: 10.1097/IGC.0b013e3182a809e0.

38.

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.

Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng K.

Invest New Drugs. 2014 Feb;32(1):113-22. doi: 10.1007/s10637-013-9956-5. Epub 2013 Apr 9.

39.

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.

Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.

PLoS One. 2013;8(3):e54014. doi: 10.1371/journal.pone.0054014. Epub 2013 Mar 14.

40.

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.

Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J.

Med Oncol. 2013 Mar;30(1):361. doi: 10.1007/s12032-012-0361-2. Epub 2012 Dec 28. Review.

PMID:
23271209
41.

Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancer.

Wu J, Ryan T, Levinson B, Newman E, Hochster HS, Muggia F.

Anticancer Res. 2012 Mar;32(3):939-45.

PMID:
22399614
42.

Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).

Wiernik PH, Li H, Weller E, Hochster HS, Horning SJ, Nazeer T, Gordon LI, Habermann TM, Minniti CJ Jr, Shapiro GR, Cassileth PA.

Leuk Lymphoma. 2012 Jun;53(6):1137-42. doi: 10.3109/10428194.2011.643406. Epub 2012 Jan 11.

43.

Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.

Yuan Y, Cohen DJ, Love E, Yaw M, Levinson B, Nicol SJ, Hochster HS.

Cancer Chemother Pharmacol. 2011 Aug;68(2):371-8. doi: 10.1007/s00280-010-1493-8. Epub 2010 Oct 27.

PMID:
20978761
44.

Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer.

Stein S, Cohen DJ, Hochster HS.

Clin Colorectal Cancer. 2010 Jun;9 Suppl 1:S44-50. doi: 10.3816/CCC.2010.s.006. Review.

PMID:
20630850
45.

Stop and go: yes or no?

Hochster HS.

J Clin Oncol. 2009 Dec 1;27(34):5677-9. doi: 10.1200/JCO.2009.24.5209. Epub 2009 Sep 28. No abstract available.

PMID:
19786651
46.

The power of "p": on overpowered clinical trials and "positive" results.

Hochster HS.

Gastrointest Cancer Res. 2008 Mar;2(2):108-9. No abstract available.

47.

Rationale for combining biotherapy in the treatment of advanced colon cancer.

Cohen DJ, Hochster HS.

Gastrointest Cancer Res. 2008 May;2(3):145-51.

48.

Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.

Marti JL, Hochster HS, Hiotis SP, Donahue B, Ryan T, Newman E.

Ann Surg Oncol. 2008 Dec;15(12):3521-31. doi: 10.1245/s10434-008-0152-3. Epub 2008 Oct 2.

PMID:
18830756
49.

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E.

J Clin Oncol. 2008 Jul 20;26(21):3523-9. doi: 10.1200/JCO.2007.15.4138. Erratum in: J Clin Oncol. 2008 Oct 1;26(28): 4697.

PMID:
18640933

Supplemental Content

Loading ...
Support Center